A US biotechnology company has tested a gene therapy designed to reverse ageing in humans for the first time.

The first participant has been treated in a landmark clinical trial of cellular reprogramming, which aims to rejuvenate ageing cells.

Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now being tested in humans.